Axsome Therapeutics to Present at Upcoming Investor Conferences
September 18 2017 - 7:00AM
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced that Herriot Tabuteau, M.D., Axsome’s Chief
Executive Officer, will present a corporate overview at the
following investor conferences:
- The Ladenburg Thalmann 2017 Healthcare
Conference in New York, NY on Tuesday,
September 26, 2017 at 9:30 AM Eastern Time.
- The Cantor Fitzgerald Global Healthcare Conference in New York,
NY on Wednesday, September 27, 2017 at 1:40 PM Eastern Time.
Live webcasts and archives of the events can be
viewed on the Investors’ section of the Company's website
at www.axsome.com
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s product candidate
portfolio includes three clinical-stage candidates, AXS-02, AXS-05,
and AXS-06. AXS-05 is currently in a Phase 3 trial in treatment
resistant depression (TRD) and a Phase 2/3 trial in agitation in
patients with Alzheimer’s disease (AD). AXS-02 is currently in
Phase 3 trials in complex regional pain syndrome (CRPS) and knee
osteoarthritis (OA) associated with bone marrow lesions (BMLs) with
an additional Phase 3 trial planned in chronic low back pain (CLBP)
associated with Modic changes (MCs). A Phase 1 trial of AXS-06 has
been completed. AXS-02, AXS-05, and AXS-06 are investigational drug
products not approved by the FDA. For more information, please
visit the company website at www.axsome.com. The company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation and
completion of the trials, futility analyses and receipt of interim
results; the timing of and our ability to obtain and maintain U.S.
Food and Drug Administration or other regulatory authority approval
of, or other action with respect to, our product candidates; the
Company’s ability to successfully defend its intellectual property
or obtain the necessary licenses at a cost acceptable to the
Company, if at all; the successful implementation of the Company’s
research and development programs and collaborations; the success
of the Company’s license agreements; the acceptance by the market
of the Company’s product candidates, if approved; and other
factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contact: Mark Jacobson Vice President,
Operations Axsome Therapeutics, Inc. 25 Broadway, 9th Floor New
York, NY 10004 Tel: 212-332-3243 Email: mjacobson@axsome.com
www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024